# Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA sequencing-based profiling of TP53

## TL;DR

This study uses DNA sequencing of the TP53 gene to connect clinical and lab models of high-grade serous ovarian cancer, helping develop better treatments.

## Contribution

The study bridges clinical and laboratory models of HGSOC using TP53 DNA sequencing and drug testing for targeted therapy development.

## Key findings

- OVCAR3 was validated as a representative model for HGSOC through TP53 profiling.
- Metformin and chlorpromazine showed effects on cell death and proliferation in both clinical and lab samples.
- Sanger sequencing successfully detected TP53 mutations, linking clinical and laboratory data.

## Abstract

The most predominant and aggressive form of ovarian cancer is high grade serous ovarian carcinoma (HGSOC), characterized by late-stage diagnosis and poor prognosis. The TP53 gene, the molecular underpinnings of this malignancy studying in vitro model to serve as a valuable. The Sanger sequencing was used for clinical and laboratory wild type TP53 gene and making it an ideal profiling to offers a precise method for detecting comparable specific gene. In this study, drug repurposing agent’s metformin, chlorpromazine (CPZ) alone and combine were tested on both clinical and laboratory ovarian cancer samples to evaluate on hemocytometer and clonogenic assay for dead cell and proliferation respectively. Following drug treatment, both samples were further analyzed using Sanger sequencing to detect TP53 profiling. The resulting data were analyzed to achieve successfully known target region and worked as a bridge between clinical and laboratory model. The insights gained from this study not only validate OVCAR3 as a representative model for HGSOC but also provide a foundation for developing targeted therapeutic strategies.